Form 8-K - Current report:
SEC Accession No. 0001193125-26-409819
Filing Date
2026-10-01
Accepted
2026-10-01 07:30:19
Documents
11
Period of Report
2026-09-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K kynb-20260930.htm   iXBRL 8-K 56347
2 EX-99.1 kynb-ex99_1.htm EX-99.1 15362
3 GRAPHIC img157578371_0.jpg GRAPHIC 10635
  Complete submission text file 0001193125-26-409819.txt   197054

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kynb-20260930.xsd EX-101.SCH 24862
14 EXTRACTED XBRL INSTANCE DOCUMENT kynb-20260930_htm.xml XML 4698
Mailing Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133
Business Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133 415-978-1200
KYNTRA BIO, INC. (Filer) CIK: 0000921299 (see all company filings)

EIN.: 770357827 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36740 | Film No.: 261428937
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)